Clinical trial NCT04756479: Mortality Due to COVID-19 in the COVID-AGEBRU Study
Official title: Predictors of Intrahospital Mortality in Older Patients Admitted Due to COVID-19 in the COVID-19 AGEBRU Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Old Age; Debility
Morbidity, Multiple
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2021-02-16
Enrollment: 160
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients aged 70 and over hospitalized in an acute care unit in Brugmann university hospital, in Belgium, due to COVID-19 in the period Mars to June 2020.

Brief summary: The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19

Detailed description: The COVID-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. Despite of the fact that the SAR-COV2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected.

The COVID-Age Brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to COVID-19

Eligibility criteria: Inclusion Criteria:

* Patients aged 70 and older
* Patients admitted to an acute care geriatric unit due to COVID-19
* Patients with COVID-19 by PCR, serology or CT scan suggestive of this disease

Exclusion Criteria:

* No other demographic or clinical exclusion criteria will be applied

Primary outcomes:
measure: All-cause mortality during hospital admission (admission up to discharge time)
timeFrame: Through study completion, an average of one month.
Secondary outcomes:
measure: Prevalence of medical diseases and geriatric syndromes
timeFrame: Through study completion, an average of one month.
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
Study officials:
affiliation: CHU Brugmann, Director of the Geriatrics Department
name: Murielle MS Surquin, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mendes A, Serratrice C, Herrmann FR, Genton L, Perivier S, Scheffler M, Fassier T, Huber P, Jacques MC, Prendki V, Roux X, Di Silvestro K, Trombert V, Harbarth S, Gold G, Graf CE, Zekry D. Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study. J Am Med Dir Assoc. 2020 Nov;21(11):1546-1554.e3. doi: 10.1016/j.jamda.2020.09.014. Epub 2020 Sep 15.
citation: Menager P, Briere O, Gautier J, Riou J, Sacco G, Brangier A, Annweiler C, Geria-Covid Study Group OBOT. Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients. 2020 Dec 24;13(1):39. doi: 10.3390/nu13010039.
citation: Miralles O, Sanchez-Rodriguez D, Marco E, Annweiler C, Baztan A, Betancor E, Cambra A, Cesari M, Fontecha BJ, Gasowski J, Gillain S, Hope S, Phillips K, Piotrowicz K, Piro N, Sacco G, Saporiti E, Surquin M, Vall-Llosera E. Unmet needs, health policies, and actions during the COVID-19 pandemic: a report from six European countries. Eur Geriatr Med. 2021 Feb;12(1):193-204. doi: 10.1007/s41999-020-00415-x. Epub 2020 Oct 15.